Abstract:Abstract Probiotics are defined as live microorganisms that confer a health benefit on the host when administered in adequate amounts. Bacillus coagulans GBI-30, 6086 (BC30) is a commercially available, lactic acid-producing, spore-forming bacteria that exhibits diverse functions. Contrary to most lactic acid-producing bacteria, B. coagulans spores can withstand extreme conditions, lending resiliency through commercial pet food processing, storage, and chemical and enzymatic digestion through the gastrointestinal tract. Previous studies in humans and livestock suggest B. coagulans have probiotic potential, although research in dogs is limited. Therefore, the objectives were to determine the effects of B. coagulans on nutrient digestibility, hematology, immunoglobulin concentrations, and fecal characteristics, metabolites, and microbiota populations of healthy adult dogs before and after an abrupt diet change. Pointer dogs [n = 12; age = 5.9 ± 2.5 yr; body weight (BW) = 26.6 ± 6.1 kg] were used in a replicated 3 × 3 Latin square design and fed commercial diets containing no probiotics or prebiotics. Probiotic or placebo capsules were administered before each daily feeding, with the following treatments tested: 1) basal diet + placebo (control; 250 mg maltodextrin); 2) basal diet + B. coagulans (low dose; 5 x 108 CFU/d); and 3) basal diet + B. coagulans (high dose; 2.5 x 109 CFU/d). An extruded kibble diet was fed to all dogs during a 28-d diet transition phase, after which dogs were abruptly switched to a commercial canned diet with fecal samples collected 2-, 6-, 10-, and 14-d after diet change. All data were analyzed using the Mixed Models procedure of SAS 9.4, with P < 0.05 being significant. Prior to dietary change, nutrient digestibility, food intake, immunoglobulin concentrations, metabolites, and hematology were not affected by treatment. However, fecal scores were decreased (P < 0.05; firmer stools) in dogs fed B. coagulans than controls. Also, fecal Faecalibacterium abundance was greater (P < 0.05) in dogs fed the low B. coagulans dose than those fed the high dose or controls. There were no interaction effects observed due to B. coagulans supplementation throughout the diet transition, but the abrupt transition to canned food reduced (P < 0.0001) fecal DM content and increased (P < 0.0001) fecal scores (looser stools) and pH. The diet transition also increased (P < 0.01) fecal Clostridium hiranonis, Collinsella, Fusobacterium, and Ruminococcus gnavus abundances and decreased (P < 0.01) fecal Bifidobacterium, Blautia, Faecalibacterium, Prevotella copri, Streptococcus, and Turicibacter abundances. Abundances of E. coli, Faecalibacterium, and Prevotella copri were modulated (P < 0.05) by B. coagulans supplementation alone. Our results demonstrate that although B. coagulans did not appear to attenuate shifts in fecal consistency and microbiota populations during an abrupt dietary change, this species may aid in maintaining stool quality and does not negatively impact nutrient digestibility or canine health.

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial

Comparison of Oral Prednisolone, Budesonide and Probiotics in the Treatment of Canine Inflammatory Bowel Disease

Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease

Clinical response in dogs with acute hemorrhagic diarrhea syndrome following randomized probiotic treatment or fecal microbiota transplant

Effects of Supplementation of Live and Heat-treated Bifidobacterium animalis subspecies lactis CECT 8145 on Glycemic and Insulinemic Response, Fecal Microbiota, Systemic Biomarkers of Inflammation, and White Blood Cell Gene Expression of Adult Dogs.

Evaluation of the effects of medium‐term (57‐day) omeprazole administration and of omeprazole discontinuation on serum gastrin and serum chromogranin A concentrations in the horse

Effects of Synbiotics on the Fecal Microbiome and Metabolomic Profiles of Healthy Research Dogs Administered Antibiotics: A Randomized, Controlled Trial

The Effect of Probiotics Supplementation on the Gut Microbiome of Healthy Dogs Assessed Using Metagenomic Sequencing: A Randomized Control Trial

Effects of probiotic bacteria in dogs with food responsive diarrhoea treated with an elimination diet*

Comparison of initial treatment with and without corticosteroids for suspected acute pancreatitis in dogs

A Randomized Double Blinded Placebo-Controlled Clinical Trial of a Probiotic or Metronidazole for Acute Canine Diarrhea

The role of diet in managing inflamatory bowel disease affected dogs: a retrospective cohort study on 76 cases

The Effect of Probiotics on Treatments in Patients Affected by Inflammatory Bowel Disease: A Systematic Review

Case Report: Oral Fecal Microbiota Transplantation in a Dog Suffering From Relapsing Chronic Diarrhea—Clinical Outcome and Follow-Up

Effects of Canine-Obtained Lactic-Acid Bacteria on the Fecal Microbiota and Inflammatory Markers in Dogs Receiving Non-Steroidal Anti-Inflammatory Treatment

Microbiota in Mild Inflammatory Bowel Disease (IBD) Can Be Modulated by Beta-Glucans and Mannanoligosaccharides: A Randomized, Double-Blinded Study in Dogs

Clinical effect of probiotics in prevention or treatment of gastrointestinal disease in dogs: A systematic review

Integrative Analysis of Gut Microbiota and Fecal Metabolites in Rats after Prednisone Treatment

Prevalence and appropriateness of omeprazole prescription in dogs at a veterinary teaching hospital before and after the publication of the ACVIM consensus statement on the rational administration of gastrointestinal protectants

PSIX-16 Effects of Bacillus coagulans GBI-30, 6086 on nutrient digestibility, fecal characteristics and metabolites, immunity, and microbiota of healthy adult dogs subjected to an abrupt diet change